About Community Pharmacy South Central
Continuously improving the quality of care we give patients and
improving the outcomes of their treatment is the core purpose of
the new NHS commissioning system.
The latest news
Information on training events and resources available for you and your team
Written by admin on Wednesday 18th October 2017
Certain pages on this news feed are only available to NPA members and hence requires members to log-in accordingly
A spokesman said: “We are pleased that the government is now looking at a range of options for maintaining a prompt medicines supply service in the event of a no-deal Brexit.
“The Government has listened to us and they are now consulting on legislative provisions to allow pharmacists certain flexibilities to make supplies under protocol.
“The NPA has been invited to comment on the proposals set out by the DHSC. We are currently in the process of preparing our detailed response.
“Government has asked manufacturers to ensure they have a minimum six weeks’ additional supply in the UK as buffer stock in case the UK leaves the EU next March with no-deal and without a transitional agreement. By itself, this is an insufficient contingency to deal with the potential disruption that might occur.
“Therefore we welcome the current consultation on contingency measures giving pharmacists the opportunity to use their clinical judgment to meet patient demand.…
In it Mr Hancock says proposals to allow the flow of goods into the UK without additional controls and checks, in the event of a no deal Brexit, are progressing well.
However, he reiterated the EU’s stance that in the event of a no deal scenario, it will impose full third country controls on people and goods entering the EU from the UK.
He added: “The cross-Government planning assumptions have been revised so we can prepare for the potential impacts that the imposition of third country controls by member states could have.
“These impacts are likely to be felt mostly on the short straits crossings into Dover and Folkestone, where the frequent and closed loop nature of these mean that both exports and imports would be affected.
“The revised cross-Government planning assumptions show that there will be significantly reduced access across the shorts straits, for up to six months.
“This is very much a worst-case scenario; however, as a responsible Government, we have a duty to plan for all scenarios.”
The Government said it recognises the vital importance of medicines and medical products and is working to ensure that there is sufficient roll-on, roll-off freight capacity to enable these vital products to continue to move freely in to the UK.…
Market Pharmacy connected to the UK Medicines Verification System last week and is thought to be the first in the country to have a product decommissioned and recommissioned.
The pharmacy is part of the Hollowood Chemists group owned by NPA board member Raj Patel MBE. Raj is a director of SecurMed UK Limited and chairs the UK FMD Working Group which brings together the main pharmacy bodies representing community pharmacy to influence and inform the implementation of FMD in the UK.
He said: “There’s no need to wait until the FMD compliance deadline in February. My pharmacies wanted to make a start now, to uncover any implementation problems and resolve them ahead of time. I’m pleased to say that everything went smoothly.”
Gareth Jones, Head of Corporate Affairs at the NPA said: “The NPA is working hard to provide as much information on FMD as possible, to help members get prepared. …
This scheme will be available for a number of years, however, a short pilot phase is open for Healthcare Professionals until Saturday 22 December 2018. Please note: this is not the deadline as the scheme will run for a number of years. Applicants need to complete an online application form, guidance is available here.
Additionally, the Department for Exiting the European Union has announced what would happen to citizens’ rights in the event of the UK leaving the EU without a deal, both for EU citizens in the UK and UK nationals in the EU.
The NPA is continuing to keep abreast on all developments relating to Brexit including meeting with senior officials in Government, MHRA and other stakeholders within the pharmacy and healthcare sector. NPA members with questions or concerns relating to Brexit are invited to contact NPA Pharmacy Services at email@example.com .
Further information and guidance is also available on GOV.UK.…
Instalment Controlled Drug (CD) prescriptions which cover pharmacy closure days over the Christmas and New Year period will need to have the correct wording on them to ensure that a legally valid supply can be made.
Each UK country (England, Northern Ireland, Scotland and Wales) allows different CD items to be prescribed by instalments and pharmacy contractors should confirm that the item is allowed on the appropriate instalment form before dispensing. NPA members are reminded to:
Prepare for the holiday period by checking all CD instalment prescriptions in preparation to ensure any errors can be resolved during the working week
Ensure sufficient stock is available to cover all supplies for the holiday period
Alert patients of the pharmacy’s opening hours over the holiday period; for example by using reminder cards, leaflets or posters
Instalment CD prescriptions should meet the following legal requirements:
Name and address of the patient
Dose, form, name and strength of the item
Total quantity in words and figures for Schedule 2 and 3 CDs – this must be expressed in terms of dosage units, for example, methadone oral solution should be expressed as ‘mls’ and not ‘mgs’
Signature and address of the prescriber
The instalment amount and the instalment intervals to be observed
Type of appropriate prescriber
Prescriber’s signature date
Additionally, instalment CD prescriptions should either:
Contain the exact dates of supply and specific details of the instalment amounts to ensure patients have sufficient medicine to cover them for days when the pharmacy is closed, or;
Contain the exact pharmacy closure wording sanctioned by the Home Office (HO) which can be handwritten, typed or stamped onto the prescription by the prescriber
The HO may not safeguard the pharmacist from any legal ramifications for making a supply against a prescription that uses unapproved wording, therefore, the pharmacist should attempt to get the prescription amended by the prescriber to state the approved wording before making a supply
Missing legal requirements
Where prescriptions are missing any legal requirements or are ambiguous, pharmacists are advised to send these prescriptions back to the prescriber to be amended to ensure that all supplies are made legally.…
We are conducting a survey* of the NPA membership, to help us prioritise our efforts on your behalf, as we strive to help you through turbulent times and into a brighter future in which you can prosper professionally and commercially. The survey should take no more than 10 minutes, and your responses will be treated in strict confidence. Please note that some of the questions in the survey are only suitable for Pharmacy Owners.
Take Survey Now
Please note: you will be directed to an external site; SurveyMonkey is a third party provider, please take a moment to familiarise yourself with their Privacy and Cookie policies. Your data will be used by the NPA as set out in our Data Protection Policy. If you have any questions, contact us at: firstname.lastname@example.org…
Drug (pack size)
Amisulpride 100mg tablets (60)
Amisulpride 200mg tablets (60)
Amisulpride 50mg tablets (60)
Buprenorphine 8mg sublingual tablets sugar free (7)
Flucloxacillin 500mg capsules (28)
Lamotrigine 100mg tablets (56)
Lamotrigine 200mg tablets (56)
Lamotrigine 50mg tablets (56)
Latanoprost 50micrograms/ml eye drops (2.5ml)
Lercanidipine 20mg tablets (28)
Nicorandil 10mg tablets (60)
Nitrofurantoin 50mg tablets (28)
Propranolol 10mg tablets (28)
Propranolol 40mg tablets (28)
Ramipril 10mg tablets (28)
Ramipril 2.5mg tablets (28)
Ramipril 5mg tablets (28)
Tadalafil 5mg tablets (28)
Valsartan 160mg capsules (28)
Valsartan 40mg capsules (28)
Valsartan 80mg capsules (28)
Following from my previous superintendent update, NHS England published updated “Quality Payments: Guidance for the February 2019 review point” (QP guidance) on 27 November 2018. I have summarised the key points very briefly in this update; I strongly recommend that the full document be read as there have been many changes compared to previous quality payments (QP) review points.
W/C Monday 3 December 2018
Automated email received to your NHSmail account from email@example.com for registering with ‘Manage Your Service’ portal.
First half of December 2018
Email received to your NHSmail account confirming whether you have met the Gateway criteria, NHS Digital Warranted Environment Specification (WES).
Monday 5 November 2018 10:00 – Friday 15 February 2019 23:59
Confirm/edit your pharmacy’s NHS 111 Directory of Service (DoS) entry
Monday 3 December 2018 00:00 – Friday 15 February 2019 23:59
You must edit/validate your NHS.UK profile entry
Monday 4 February 2019 at 09:00 – Friday 1 March 2019 at 23:59
Friday 8 February 2019 17:00
Pharmacy contractors requesting NHS.UK website editing dates via their shared NHSmail account prior to this date will be assured of having it enabled.…
Ballot papers have been dispatched for the region, which the NPA terms Area 10. Olivier Picard and James Timbs are the candidates.
The deadline for ballot papers to be received is 12 noon on Wednesday December 19.
More information about the role and responsibilities of NPA board members is available here
Anyone with any queries can contact the NPA’s returning officer via firstname.lastname@example.org…
Class 2 medicines recall – Action within 48 hours
Ref: MDR 094-06/18
Date 30 November 2018
Product name Valsartan-containing products
(Manufactured by Teva UK Limited and Mylan)
A Class 2 medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for batches of valsartan-containing products; these include:
Certain batches supplied by Teva UK Limited
All unexpired batches supplied by Mylan
The affected batches of valsartan-containing products may be contaminated with a nitrosamine contaminant, N‑nitrosodiethylamine (NDEA) which is potentially carcinogenic and genotoxic.
Advice for pharmacy teams
Pharmacy teams should refer to the recalled batches/products listed on the MHRA website to check their current stock of valsartan-containing products and return to the supplier.
MHRA does not envisage a stock shortage of valsartan-containing products; however, if there are local supply issues, the patient should speak to their prescriber for an alternative.
Advice for patients
Patients should not stop taking their valsartan-containing medicine because the health risk of discontinuing the medicine is greater than the potential risks of the contaminant.…